Agilent enters digital pathology with Visiopharm deal

By LabPulse.com staff writers

September 2, 2021 -- Agilent Technologies and Visiopharm have signed a worldwide distribution agreement that allows Agilent to co-market Visiopharm's portfolio of digital pathology software. The deal represents Agilent's entry into digital pathology.

Visiopharm's artificial intelligence-driven precision pathology software products have the CE Mark for in vitro diagnostic devices. The products are designed to improve diagnostic accuracy and workload management for pathologists, according to Agilent.

The companies will initially focus their efforts on Europe. The deal strengthens the long-term relationship between the two companies, Agilent said.

Agilent secures expanded CE Mark for cancer assay
Agilent Technologies has received an expanded CE Mark that will allow its PD-L1 IHC 22C3 pharmDx assay -- a companion diagnostic for the Keytruda chemotherapy...
Scientists develop spectroscopy-based COVID-19 triage tool
Attenuated total reflection Fourier-transform infrared spectroscopy is a rapid, low-cost tool that can be used to triage the severity of illness in patients...
Liquid biopsy may detect ALK fusions in lung cancer patients
The use of next-generation sequencing-based circulating-tumor DNA in liquid biopsies may detect novel anaplastic lymphoma kinase (ALK) fusions in lung...
Agilent updates Visiopharm image analysis software
Agilent Technologies has released an updated version of its Visiopharm image analysis software. The software now incorporates HercepTest monoclonal antibody...
Digital pathology woos new users, thrives in pandemic market
The COVID-19 pandemic, while disrupting healthcare in general, also provides a selling point as many pathologists are now working from home, writes Bruce...

Copyright © 2021 LabPulse.com

Last Updated np 9/7/2021 8:42:42 AM